Are fundamental tailwinds a stronger play than volatile markets? 6 mid-cap pharma stocks with an upside potential of over 22%

The Indian pharmaceutical sector has undergone significant changes over the past decade, marking a transition from a period of consolidation and valuation readjustment to one where the focus has shifted towards more sustainable and compliant operational practices. This transformation is a shift in the strategic approach adopted by pharma companies. Historically, the expansion strategies of many companies were driven by optimistic PowerPoint presentations that forecast market growth. Then came the reality check, where the US FDA made all of them relook at what they were doing. After a long time, some of the mid-sized players have also reached an inflection point where it might be time to look at them without the bias of the past.